Uno studio per valutare la sicurezza, la farmacocinetica e l'efficacia preliminare della terapia IDE574 in partecipanti adulti con tumori solidi avanzati
An Open Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of IDE574 as Monotherapy in Locally Advanced or Metastatic Solid Tumors and as Combination Therapy With Fulvestrant in Locally Advanced or Metastatic Cancer
IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7.
The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants with locally advanced or metastatic solid tumors and as combination therapy with fulvestrant in participants with advanced or metastatic cancer.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Part 1 - Monotherapy Dose Escalation and Expansion:
Part 1A - Monotherapy Dose Escalation Part 1A will evaluate increasing doses of IDE574 to assess safety, tolerability and to determine dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD) or the recommended dose for expansion (RDE) in subjects with advanced or metastatic cancer.
Part 1B - Monotherapy Dose Expansion Part 1B will evaluate in ER+ HER2- advanced or metastatic cancer at one RDE determined from Part 1A or the MTD.
Part 1C - Exploratory Food Effect Sub-study
Part 2 - Combination Dose Escalation and Expansion
Part 2A - IDE574 Combination Therapy with Fulvestrant Dose Escalation Part 2A will evaluate participants with advanced or metastatic cancer with escalating doses of IDE574 in combination with fulvestrant to assess safety, tolerability and to determine DLTs, MTD or RDE.
Part 2B - IDE574 Combination Therapy with Fulvestrant Dose Expansion Part 2B will randomly assign participants with advanced or metastatic cancer to dose levels selected from Part 2A
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 1
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: IDEAYA Clinical Trials
- Numero di telefono: +1-855-433-224
- Email: IDEAYAClinicalTrials@ideayabio.com
Luoghi di studio
-
-
K'alak'i T'bilisi
-
Batumi, K'alak'i T'bilisi, Georgia, 6000
- Reclutamento
- High Technology Hospital MedCenter Ltd
-
Investigatore principale:
- Tamta Makharadze, MD
-
Contatto:
- Mamuka Sikharulidze
- Numero di telefono: +995 568 999 559
- Email: sikharulidzemamuka3@gmail.com
-
Tbilisi, K'alak'i T'bilisi, Georgia, 114
- Reclutamento
- Pineo Medical Ecosystem
-
Contatto:
- Nino Kekenadze
- Numero di telefono: +995 593 660 940
- Email: Nkekenadze@pineo.ge
-
Investigatore principale:
- Mziuri Zakaraia, MD
-
Tbilisi, K'alak'i T'bilisi, Georgia, 112
- Attivo, non reclutante
- LLC ARENSIA Exploratory Medicine
-
Tbilisi, K'alak'i T'bilisi, Georgia, 144
- Attivo, non reclutante
- Geo Hospitals Multiprofile Medical Center Tbilisi
-
Tbilisi, K'alak'i T'bilisi, Georgia, 186
- Attivo, non reclutante
- LLC Caucasus Medical Centre
-
-
-
-
California
-
Santa Monica, California, Stati Uniti, 90404-2095
- Attivo, non reclutante
- UCLA - Parkside Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, Stati Uniti, 06510-3206
- Reclutamento
- Yale School of Medicine - Cedar Street
-
Investigatore principale:
- Patricia LoRusso, MD
-
Contatto:
- Karen Seely
- Numero di telefono: 203-314-3303
- Email: karen.rodriguezvasquez@yale.edu
-
-
Florida
-
Plantation, Florida, Stati Uniti, 33322
- Reclutamento
- Florida Clinical Trials Group
-
Investigatore principale:
- Harshad Amin, MD
-
Contatto:
- Sandra Perez
- Numero di telefono: 772-297-3057
- Email: perezs@floridactg.com
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30322-1013
- Reclutamento
- Winship Cancer Institute, Emory University
-
Investigatore principale:
- Shipra Gandhi, MD
-
Contatto:
- Alejandra Bono
- Numero di telefono: 404-778-0954
- Email: alejandra.maria.bono@emory.edu
-
-
Missouri
-
St Louis, Missouri, Stati Uniti, 63110-1010
- Reclutamento
- Washington University - Siteman Cancer Center
-
Investigatore principale:
- Faisal Fa'ak, MD
-
Contatto:
- Pamela Coe
- Numero di telefono: 314-747-7569
- Email: mpamela@wustl.edu
-
-
New Jersey
-
East Brunswick, New Jersey, Stati Uniti, 08816
- Reclutamento
- START Astera, LLC
-
Investigatore principale:
- Bruno Fang, MD
-
Contatto:
- Bruno S Fang
- Numero di telefono: 732-426-4750
- Email: info@startresearch.com
-
-
New York
-
Lake Success, New York, Stati Uniti, 11042
- Reclutamento
- START New York Long Island, LLC
-
Investigatore principale:
- Geraldine O'Sullivan Coyne, MD
-
Contatto:
- Geraldine O'Sullivan Coyne
- Numero di telefono: 363-207-5160
- Email: g.osullivancoyne@startresearch.com
-
New York, New York, Stati Uniti, 10032-3729
- Attivo, non reclutante
- Columbia University Medical Center -161 Fort Washington
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37203
- Reclutamento
- SCRI Oncology Partners - PPDS
-
Investigatore principale:
- Sarah Premji, MD
-
Contatto:
- Connor Frost
- Numero di telefono: 615-478-3475
- Email: connor.frost@scri.com
-
-
Texas
-
Austin, Texas, Stati Uniti, 78758
- Reclutamento
- NEXT Texas LLC - Austin
-
Investigatore principale:
- Sheena Sahota, MD
-
Contatto:
- Heather Watson
- Numero di telefono: 737-610-5202
- Email: nxtaus_coordinators@nextoncology.com
-
Dallas, Texas, Stati Uniti, 75039
- Reclutamento
- NEXT Texas LLC - Dallas
-
Investigatore principale:
- Faran Polani, MD
-
Contatto:
- Carmen Gonzalez
- Numero di telefono: 210-580-9479
- Email: NXTDFW_Coordinators@nextoncology.com
-
Fort Worth, Texas, Stati Uniti, 76104
- Reclutamento
- START Dallas Fort Worth, LLC
-
Investigatore principale:
- Henry Xiong, MD
-
Contatto:
- Henry Xiong
- Numero di telefono: 682-350-3010
- Email: info@startresearch.com
-
Houston, Texas, Stati Uniti, 77030-4009
- Reclutamento
- MD Anderson Cancer Center
-
Investigatore principale:
- Timothy Yap, MD
-
Contatto:
- Desirae Dufner
- Numero di telefono: 713-524-3434
- Email: DDufner@mdanderson.org
-
Houston, Texas, Stati Uniti, 77054
- Reclutamento
- NEXT Texas LLC - Houston
-
Investigatore principale:
- Jennifer Segar, MD
-
Contatto:
- Carmen Gonzalez
- Numero di telefono: 210-580-9479
- Email: nxthou_coordinators@nextoncology.com
-
San Antonio, Texas, Stati Uniti, 78229
- Reclutamento
- NEXT Texas LLC - San Antonio
-
Investigatore principale:
- David Sommerhalder, MD
-
Contatto:
- April Guerra
- Numero di telefono: 210-580-9500
- Email: NXTSA_Coordinators@nextoncology.com
-
San Antonio, Texas, Stati Uniti, 78229
- Reclutamento
- Start San Antonio, LLC
-
Investigatore principale:
- Amita Patnaik, MD
-
Contatto:
- Hector Navarro
- Numero di telefono: 210-593-5700
- Email: Hector.Navarro@startresearch.com
-
-
Utah
-
West Valley City, Utah, Stati Uniti, 84119
- Reclutamento
- START Mountain Region, LLC
-
Investigatore principale:
- William McKean, MD
-
Contatto:
- William B McKean
- Numero di telefono: 1 (801) 907-4750
- Email: info@startresearch.com
-
-
Virginia
-
Fairfax, Virginia, Stati Uniti, 22031
- Reclutamento
- NEXT Virginia
-
Investigatore principale:
- Mohamad Salkeni, MD
-
Contatto:
- Maybelle De La Rosa
- Numero di telefono: 703-783-4518
- Email: nxtvir_coordinators@nextoncology.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
Archival Tissue sample for testing
- Part 1A - Participants with advanced or metastatic cancer who have progressed on/after standard of care therapy or are intolerant to additional effective therapies.
- Female participants with cancer considered to be of childbearing potential (or have tubal ligations only) must be willing to undergo medically induced menopause (Parts 2A and B only)
- Female participants of nonchildbearing potential with cancer must meet at least 1 of the following criteria: Age ≥ 60 years or age <60 years with absence of menstruation for at least 12 months, or had prior removal of both ovaries
- Have Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤1.
- Have adequate bone marrow, renal and liver function.
- Life expectancy of >3 months
- Able to safely administer and retain orally administered study treatment
- Able to comply with contraceptive/barrier requirements
Key Exclusion Criteria:
- Known symptomatic brain metastases or leptomeningeal metastasis
- Known primary CNS malignancy and any other malignancies within 2 years prior to the first dose with the exception of adequately treated localized tumor.
- Have impairment of GI function or GI disease that may significantly alter the absorption of IDE574.
- Have active liver or biliary disease.
- Have active, uncontrolled bacterial, fungal, or viral infection
- Have clinically significant cardiac abnormalities and/or blood clotting events within 6 months before the first dose
- If participants had adverse reactions to previous experimental antitumor treatment that have not recovered to Grade ≤ 1
- Prior irradiation to >25% of the bone marrow.
- Known or suspected hypersensitivity to IDE574/excipients or components (Parts 1 & 2) or fulvestrant/excipients or components (Part 2 only)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Monotherapy Dose Escalation (Part 1A)
Participants with the appropriate tumor types will be treated with escalating doses of IDE574 |
IDE574 |
|
Sperimentale: Monotherapy Dose Expansion (Part 1B)
Participants with advanced or metastatic cancer will be treated using the RDE or MTD of IDE574 |
IDE574 |
|
Sperimentale: Combination Dose Escalation (Part 2A) IDE574 + Fulvestrant
Participants with advanced or metastatic cancer will be treated with escalating doses of IDE574 in combination with fulvestrant |
IDE574 Fulvestrant Injection |
|
Sperimentale: Combination Dose Expansion (Part 2B)
Participants with advanced or metastatic cancer will be randomly assigned to doses of IDE574 + Fulvestrant |
IDE574 Fulvestrant Injection |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Safety and Tolerability of IDE574 in Part 1 A Monotherapy Dose escalation
Lasso di tempo: Following the first dose of IDE574
|
incidence of DLT; incidence and severity of AEs/serious adverse events (SAEs) graded based on CTCAE V6.0 |
Following the first dose of IDE574
|
|
Safety and Tolerability of IDE574 in Part 1B Monotherapy Dose expansion based on incidence and severity of AEs/SAEs
Lasso di tempo: total study duration
|
Incidence and severity of AEs/SAEs graded based on CTCAE V6.0 |
total study duration
|
|
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on the ORR per RECIST version 1.1
Lasso di tempo: total study duration
|
Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
|
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on DOR per RECIST version 1.1.
Lasso di tempo: total study duration
|
Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
|
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2A Combination Dose Escalation based on incidence of DLT
Lasso di tempo: total study duration
|
Incidence of DLT; incidence and severity of AEs/SAEs graded based on CTCAE V6.0 |
total study duration
|
|
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the incidence and severity of AEs/SAEs
Lasso di tempo: total study duration
|
Incidence and severity of AEs/SAEs graded based on CTCAE V6.0 |
total study duration
|
|
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the ORR per RECIST version 1.1
Lasso di tempo: total study duration
|
Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
|
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on DOR per RECIST version 1.1.
Lasso di tempo: total study duration
|
Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response |
total study duration
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on the ORR per RECIST version 1.1
Lasso di tempo: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on DOR per RECIST version 1.1.
Lasso di tempo: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Clinical Benefit Rate (CBR)
Lasso di tempo: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Disease control rate
Lasso di tempo: total study duration
|
total study duration
|
|
Evaluate the pharmacokinetics (PK) of IDE574 in Part 1A Monotherapy Dose Escalation
Lasso di tempo: total study duration
|
total study duration
|
|
Evaluate the PK of IDE574 in Part 1B Monotherapy Dose Expansion
Lasso di tempo: total study duration
|
total study duration
|
|
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion
Lasso di tempo: total study duration
|
total study duration
|
|
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion based on DCR for other solid tumor types
Lasso di tempo: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on ORR per RECIST version 1.1
Lasso di tempo: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on DOR per RECIST version 1.1
Lasso di tempo: total study duration
|
total study duration
|
|
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on CBR per RECIST version 1.1
Lasso di tempo: total study duration
|
total study duration
|
|
Evaluate the PK of IDE574 in Part 2A Combination Dose Escalation
Lasso di tempo: total study duration
|
total study duration
|
|
Evaluate antitumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on CBR per RECIST version 1.1
Lasso di tempo: total study duration
|
total study duration
|
|
Evaluate the PK of IDE574 in Part 2B Combination Dose Expansion
Lasso di tempo: total study duration
|
total study duration
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- IDE574-001
- 178299 (Altro identificatore: Regulatory Agency Identifier Number (s))
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .